Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10510 Phase I Study in Healthy Subjects and Subjects with Elevated LDL-C
NCT07001787Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of HS-10510 in dyslipidemia and hypercholesterolemia (6 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Number of subjects with Adverse Events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
HS-10510
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT07001787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001787.